Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

Studies Show ABT-263 and ABT-869 to be Promising in Targeting Cancer Cells'

Underlying Mechanisms

ABBOTT PARK, Ill., May 15 /PRNewswire-FirstCall/ -- Abbott scientists will highlight the latest clinical trial data of several investigative compounds in the company's oncology pipeline at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 in Chicago. The presentations include ABT-263, a Bcl-2 family protein antagonist, and ABT-869, an oral small molecule that provides simultaneously potent and specific inhibition of the VEGFR and PDGFR families. Both compounds were discovered by Abbott scientists and are being co-developed by Abbott and Genentech. The company's meeting abstracts are available online today at http://www.asco.org.

By targeting a key survival mechanism of cancer cells, Abbott scientists identified ABT-263 as a potent inhibitor of Bcl-2 family proteins. The Bcl-2 family proteins regulate apoptosis (programmed cell death), the natural process by which damaged or unwanted cells die and are cleared from the body. When this process is defective, damaged cells can continue to divide, leading to the formation and growth of tumors. Preclinical studies showed promising activity against chronic lymphocytic leukemia (CLL), lymphomas and small cell lung cancer -- Phase I/II trials are currently underway in these diseases.

Additionally, Abbott scientists are targeting another vital characteristic of cancer cells with ABT-869. In early studies, data have shown that ABT-869 inhibits a distinct set of kinases that are involved in angiogenesis, a process by which tumors gain access to new blood vessels. Inhibition of these kinases may suppress tumor growth by cutting off tumor blood supply. ABT-869 is currently being tested against several tumor types in Phase II clinical trials.

"Researchers from around the world have requ
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... TN (PRWEB) March 29, 2015 North ... several PT Online Continuing Education Courses . ... 10.0 hours of CME - TPTA, approval # 56399TX ... the evaluation of the shoulder complex - 10.5 hours ... Approved #56400TX , Examination and Treatment of the SI ...
(Date:3/28/2015)... 2015 Could genetic code determine someone’s ... study by researchers at the Harvard T.H. Chan ... support of the Coffee and Caffeine Genetics Consortium and ... past fall, the study—one of several recent HSPH investigations ... from more than 120,000 regular coffee drinkers of European ...
(Date:3/28/2015)... March 28, 2015 Thousands of ... manufactured by C.R. Bard, Inc. continue to move ... District Court, Southern District of West Virginia, where ... on the Plaintiffs’ Steering Committee. According to ... granted certain defendants named in those lawsuits leave ...
(Date:3/28/2015)... An article in Fortune on Monday, March ... to organizations that deal with PCI (Payment Card Information); ... security, is worsening . Using numbers from Verizon’s ... category out of the twelve measured improved, barring one ... craziness that has gone on in the retail industry ...
(Date:3/28/2015)... How best to treat and recover from ... medicine. While diagnostic hip injections are commonly performed for ... research presented today at the American Orthopaedic Society for ... pain relief from this diagnostic injection may not predict ... study looked to assess if the amount of pain ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2
... the aftereffects of a chlorine gas disaster in a South ... to expect and how to prepare emergency response systems for ... The study is now available in the January 2009 issue ... , "This is one of the largest community exposures to ...
... symptoms are highly prevalent in different geographic populations ... the lives of those affected. Examples include GERD, ... These problems have an impact on the individual,s ... community-based research evaluating the impact of chronic gastrointestinal ...
... Multi-Serve Canisters Make it Easy to Mix with Water ... 2009 quickly approaches, Americans will begin making New Year,s ... According to this year,s survey from FranklinCovey Products ... licensee of consumer products for FranklinCovey Co, , ...
... Fisher Vista, LLC has reported,its seventh consecutive year of ... core product HRmarketer.com and strong demand for media,relations and ... The HRmarketer Services Group, established ... Services Group provides HR vendors with a,one-stop source for ...
... ARAY ), a global leader in the ... scheduled to present at the 11th Annual Needham Growth ... 2009 at 11:00 a.m. EST (8:00 a.m. PST).A live ... the investor relations page of the Company,s Web site ...
... Walks Drive Home Importance of Awareness and Education of ... effort to raise money for The Kidney TRUST(TM) -- ... chronic kidney disease (CKD) -- DaVita Inc., the nation,s ... the 3rd annual "Kidney Awareness Time(TM)" Walk-a-thon (The KAT ...
Cached Medicine News:Health News:New study examines effects of Graniteville, S.C., chlorine gas disaster 2Health News:New study examines effects of Graniteville, S.C., chlorine gas disaster 3Health News:Chronic gastrointestinal symptoms in Korean population 2Health News:Ocean Spray(R) Announces Sugar-Free Drink Mixes - A Sweet Way for Dieters to 'Stick' to Their Resolutions 2Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 2Health News:Accuray Incorporated to Present at 11th Annual Needham Growth Stock Conference 2Health News:Thousands of DaVita Teammates Raise Over $100,000 for CKD Programs 2Health News:Thousands of DaVita Teammates Raise Over $100,000 for CKD Programs 3
(Date:3/27/2015)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... announced registered offering of common shares in ... the Offering, the Company issued 7,286,432 common shares at ... proceeds of approximately $1.45 billion. On March 18, 2015, ... Commission a final prospectus supplement to its effective shelf ...
(Date:3/27/2015)... , March 27, 2015 As ... shipments of incontinence devices for women. ... the most gratifying part is the hundreds of ... women whose lives have been positively impacted by ... of InControl. InControl recently released Apex, ...
(Date:3/27/2015)... 2015   Hospira, Inc. (NYSE: ... the world,s leading provider of injectable drugs and ... evaluation of biosimilarity of its proposed biosimilar, Epoetin ... (FDA) conditionally approved name of RETACRIT™, compared to ... study data were presented at the National Kidney ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... Primary Endpoint of the Trial to Be Clarified ... Arbios Systems, Inc.,(OTC Bulletin Board: ABOS) announced today ... U.S. Food and Drug Administration ("FDA") of,an Investigational ... for SEPET(TM), Arbios, extracorporeal (outside the body) artificial,liver ...
... Feb. 21 Accumetrics, Inc. a privately-held,medical device ... tests that,measure patient response to antiplatelet drugs, announced ... Series D financing. The syndicate was led by,Arnerich ... Also participating,in the round were previous investors: Essex ...
Cached Medicine Technology:Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 2Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 3Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 4Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial 2
Silicone Foley Catheters 2-Way (Pediatric)...
Midstream Catch Kits...
Midstream Catch Kits...
... The Pediatric BladderScan® is ... Diagnostic Ultrasound's trusted family ... enabling healthcare providers to ... volume noninvasively, this easy-to-use, ...
Medicine Products: